23andMe to Report FY2024 First Quarter Financial Results
25 Julho 2023 - 5:05PM
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human
genetics and biopharmaceutical company with a mission to help
people access, understand, and benefit from the human genome,
announced today that it will report financial results for the
fiscal year 2024 (FY2024) first quarter after the market closes on
Tuesday, August 8, 2023. The Company will webcast a conference call
at 4:30 p.m. Eastern Time on that date to discuss the quarter’s
financial results and report on business progress.
The webcast can be accessed on the day of the event at
https://investors.23andme.com/news-events/events-presentations. A
webcast replay will be available at the same address for a limited
time within 24 hours after the event.
In addition, 23andMe will use the Say Technologies platform to
allow retail and institutional shareholders to submit and upvote
questions to management in advance of the earnings conference call.
Starting today, shareholders can submit questions by visiting
https://app.saytechnologies.com/23andme-2024-q1. The Q&A
platform will remain open until 24 business hours before the
earnings call.
About 23andMe23andMe is a genetics-led consumer
healthcare and therapeutics company empowering a healthier future.
For more information, please visit investors.23andme.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, including, without
limitation, statements regarding the future performance of
23andMe’s businesses in consumer genetics and therapeutics and the
growth and potential of its proprietary research platform. All
statements, other than statements of historical fact, included or
incorporated in this press release, including statements regarding
23andMe’s strategy, financial position, funding for continued
operations, cash reserves, projected costs, plans, and objectives
of management, are forward-looking statements. The words
"believes," "anticipates," "estimates," "plans," "expects,"
"intends," "may," "could," "should," "potential," "likely,"
"projects," “predicts,” "continue," "will," “schedule,” and "would"
or, in each case, their negative or other variations or comparable
terminology, are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. These forward-looking statements are predictions
based on 23andMe’s current expectations and projections about
future events and various assumptions. 23andMe cannot guarantee
that it will actually achieve the plans, intentions, or
expectations disclosed in its forward-looking statements and you
should not place undue reliance on 23andMe’s forward-looking
statements. These forward-looking statements involve a number of
risks, uncertainties (many of which are beyond the control of
23andMe), or other assumptions that may cause actual results or
performance to differ materially from those expressed or implied by
these forward-looking statements. The forward-looking statements
contained herein are also subject generally to other risks and
uncertainties that are described from time to time in the Company’s
filings with the Securities and Exchange Commission, including
under Item 1A, “Risk Factors” in the Company’s most recent Annual
Report on Form 10-K, as filed with the Securities and Exchange
Commission, and as revised and updated by our Quarterly Reports on
Form 10-Q and Current Reports on Form 8-K. The statements made
herein are made as of the date of this press release and, except as
may be required by law, 23andMe undertakes no obligation to update
them, whether as a result of new information, developments, or
otherwise.
ContactsInvestor Relations Contact:
investors@23andMe.comMedia Contact:
press@23andMe.com
23andMe (NASDAQ:ME)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
23andMe (NASDAQ:ME)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024